Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,
Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to ...
Axios Vitals on MSN4d
Express Scripts sues FTC over report about pharmacy benefit managersCigna's Express Scripts filed a lawsuit Tuesday challenging a federal report that places the blame for rising drug prices on ...
Cigna Group’s Express Scripts sued the US Federal Trade Commission over a recent report that the company said demonizes ...
The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company and other ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback